🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This phase Ib trial finds the best dose and side effects of ensartinib and ...
Status
Active Not Recruiting
Location
M D Anderson Cancer Center
Start Date
2021-03-18
Trial ID
NCT04837716
Treatments Being Tested
This is a prospective, multi-center, single-arm, phase 2 study aiming to as...
Status
Recruiting
Location
Jun Feng Liu
Start Date
2022-05-01
Trial ID
NCT05241028
Treatments Being Tested
The main objective of this study is to evaluate the bioequivalency of two p...
Status
Completed
Location
Shanghai Public Health Clinical Center
Start Date
2018-06-11
Trial ID
NCT03536481
Treatments Being Tested
This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studie...
Status
Terminated
Location
CTCA at Western Regional Medical Center
Start Date
2019-07-25
Trial ID
NCT03737994
Treatments Being Tested
This is the first human study to use X-396 (ensartinib), a drug being devel...
Status
Completed
Location
City of Hope National Med Ctr
Start Date
2012-06
Trial ID
NCT01625234
Treatments Being Tested
To assess treatment effectiveness and safety of oral X-396 capsule (Ensarti...
Status
Unknown
Location
Chest hospital affiliated to Shanghai jiao tong university
Start Date
2018-06-15
Trial ID
NCT03608007
Treatments Being Tested
To assess efficacy and safety of oral X-396 (Ensartinib) capsule in Chinese...
Status
Active Not Recruiting
Location
Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center
Start Date
2019-04-12
Trial ID
NCT03753685
Treatments Being Tested
This double-blind, randomized, placebo-controlled, multicenter, Phase III s...
Status
Recruiting
Location
TianJin Medical University Cancer Institute & Hospital
Start Date
2022-05-24
Trial ID
NCT05341583
Treatments Being Tested
This was a Phase 1/2, open-label, multicenter, single-arm study of combinat...
Status
Completed
Location
Research Facility
Start Date
2017-05-10
Trial ID
NCT02898116
Treatments Being Tested
After the use of second-generation ALK-TKI drug resistance, about 50% of ti...
Status
Unknown
Location
Sun Yat-sen University
Start Date
2021-12-01
Trial ID
NCT05178511
Treatments Being Tested